PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.
加利福尼亞州聖何塞2024年6月3日（環球新聞電線） - PROCEPT BioRobotics (納斯達克: PRCT) (本公司), 一家專注於發展泌尿學領域變革性解決方案的外科機器人公司，今日宣佈公司管理層成員將在麻省波士頓舉行的2024 Truist Securities MedTech大會上進行演講。管理層的演講安排在6月18日星期二下午1:20美國東部時間。
A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
公司網站的“投資者”部分將提供每個活動的現場網絡廣播以及存檔記錄：https://ir.procept-biorobotics.comwebcasts將存檔，並在活動之後的至少90天內提供重播。
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
關於PROCEPT BioRobotics公司
PROCEPT BioRobotics是一家外科機器人公司，專注於開發泌尿學領域的革命性解決方案，旨在推進患者護理。PROCEPT BioRobotics開發、製造和銷售AquaBeam機器人系統，這是一種先進的、圖像引導的、微創泌尿科手術機器人系統，最初的重點是治療良性前列腺增生症（BPH）。BPH是最常見的前列腺疾病，影響着約4000萬男性在美國。PROCEPT BioRobotics設計了AquaBeam療法，以爲因BPH導致的下尿路症狀（LUTS）的男性提供有效、安全和持久的治療效果，這與前列腺大小和形狀或外科醫生的經驗無關。該公司已經開發了大量的臨床證據，其中包括九項臨床研究和150多篇同行評審的出版物，支持AquaBeam療法的益處和臨床優勢。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投資者聯繫人：
Matt Bacso
副總裁，投資者關係和業務運營
m.bacso@procept-biorobotics.com
譯文內容由第三人軟體翻譯。